Participants 115 123 5
melanoma
Participants 134 315 7
Nearly 2000 patients with stage IIB and III melanoma have participated in four multicenter, randomized trials, conducted by the Eastern Cooperative Oncology Group and the Intergroup
Participants 697 740 3
patients in E1684, E1690, E1694, and E2696.
Participants 819 868 5
713 patients randomized to high-dose IFN-alpha 2b
Participants 1729 1773 3
In patients with high-risk resected melanoma
